Phase 1 N=15 Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
Cancer
Primary: Number of Adverse Events From Escalating Doses of NGR-hTNF in Combination With a Fixed Dose of Doxorubicin — 59; 142; 67; 101 Adverse event
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=197 Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.
Infections, Streptococcal
Primary: Number of Subjects With Bacterial Aetiology, Assessed by Culture Growth, From Bronchoalveolar Lavage (BAL) Fluid Samples — 141; 49; 1; 58 Participants
Phase 3 N=52 Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
Primary Immunodeficiency
Primary: AUC in the IV Phase and SC Phases: Steady-state AUC of Total IgG Over a Regular Dosing Interval — 207921.5; 213141.4 h*mg/dL
N/A N=1,420 Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)
Coronary Disease
Primary: Proportion of Subjects With Device Related Adverse Events. — 0 Proportion of subjects
Phase 3 N=1,553 E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study
Contraception
Primary: The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of…
N/A N=2,032 Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
Respiratory Tract Infections · Urinary Tract Infections
Primary: Number of Participants With Adverse Events — 10; 4; 6; 10 Participants — p=0.05
N/A N=214 Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques
Stable Angina
Primary: Percentage of Participants With Major Adverse Cardiac Events(MACE) — 1.72; 6.86 percentage of participants
N/A N=45 Hydroxyzine Dihydrochloride Premedication is a Necessity for Strabismus Surgery
Strabismus · Reflex, Oculocardiac · Hydroxyzine
Primary: Heart Rate-1 — 114.4; 125.8; 122.3 beats per minute
Phase 1 N=24 Daylight Photodynamic Therapy for Actinic Keratosis
Actinic Keratoses
Primary: Change in Treatment Symptoms — 3.9; 0.5; 0.37 score on a scale
N/A N=19 Evaluation of a Novel Product for the Removal of Impacted Human Cerumen (Earwax)
Cerumen Impaction of Both Ears
Primary: Percentage of Ears That Showed Change in Visualization of the Tympanic Membrane (Ear Drum) Following 15 or 30 Minutes of Using the Test Product — 53.3; 85.7 percentage…
Phase 1 N=142 Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers
Primary: Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max] — 474.269; 425.578 ng/mL
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
Phase 2 N=10 Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
Primary: Change From Baseline in 18F-EF5 Standardized Uptake Values (SUV) — 1.49 SUVmax
Phase 2 N=28 Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma
Small Cell Lung Cancer
Primary: Antitumour Activity Defined as Progression Free Survival (PFS) — 3.2 months
N/A N=30 Virtual Reality Experience in First Trimester D&C
First Trimester Abortion · Virtual Reality
Primary: Number of Participants Able to Use VR Device Throughout the Entire Duration of First Trimester Surgical Abortion. — 6 participants